About TALi^®

TALi’s patented technology utilizes new mechanisms specifically engineered to assess, target, and improve attention in early childhood (ages 3-8) and is delivered through an engaging video game experience. Combining over 25 years of research in developmental psychology and cognitive neuroscience, TALi’s training program has demonstrated improved attention in both neurodiverse and neurotypical children, specifically showing improvements in numeracy skills, gains in selective attention skills, and behavioral improvements in a classroom setting. Study data have been published in multiple peer-reviewed papers. The technology is currently available in Australia, India, Singapore and Hong Kong, marketed as TALi DETECT^® (screening) and TALi TRAIN^® (attention training).

The deal

The terms of the deal, estimated at $37.5M in future contingent milestone payments plus royalties on potential revenues, are structured to leverage each organization’s expertise. Building on their collective clinical development experience and Akili’s success in bringing EndeavorRx through the U.S. regulatory process and to market, the companies will work together to execute clinical trials of the TALi technology in pediatric ADHD and pursue U.S. Food and Drug Administration (FDA) regulatory clearance. Under the terms of the agreement, Akili will lead U.S. commercialization and roll-out.

Akili and the PDTs

Understanding Prescription Digital Therapeutics: Prescription Digital Therapeutics (PDTs) are clinically validated software-based interventions that prevent, manage, or treat a medical disease or disorder. PDTs are approved by regulators and available by prescription for use alone or alongside other medications or medical devices. Akili is creating PDTs informed by decades of neuroscience and cognitive research and delivered through high-quality video game experiences to treat cognitive impairments across multiple diseases and disorders.

Through this agreement, Akili is expanding its leadership in prescription digital therapeutics (PDTs) for cognitive impairments and charting a path for a new patient demographic to benefit from innovative technologies proven to improve attention. TALi’s technology builds on Akili’s product portfolio and complements its flagship product EndeavorRx^®, which is FDA-cleared to improve attention function in children ages 8-12 with ADHD.

A word from Akili’s CEO and from TALi’s MD

Akili is continuously seeking opportunities to expand our suite of targeted treatments for cognitive impairments, including through strategic collaborations with companies that share our commitment to delivering high-quality patient experiences built on scientific rigor, stated Eddie Martucci, PhD, Akili’s co-founder and CEO. Focused on early childhood intervention targeting attention, TALi’s impressive technology is an ideal addition to Akili’s portfolio. We are committed to changing the way people think about medicine, and strategic agreements like this will allow us to expand our vision to treat cognitive impairments in entirely new ways and usher in the next generation of digital therapeutics.

Akili is leading the digital therapeutics industry with its ability to dramatically scale into mainstream medicine while maximizing value to patients and to the business, making it an ideal partner for expanding the reach and impact of our technology, said Glenn Smith, Managing Director of TALi. We’re looking forward to working with the Akili team to provide solutions that deliver digital-first support to the millions of children living with attention issues.

Gerry Chillè Partner – Head of Digital Therapeutics at Healthware Group

Born and raised in Italy, then professionally baked in the US, Gerry Chillè is a unique multi-cultural individual with a polymorphous approach to problem solving and a true out-of-the-box thinker thanks to his extensive creative, technical and strategic background.
Gerry launched Healthware Labs in NYC to advance Healthware’s reach in the US innovation ecosystem and provide an Open Innovation platform for pharma clients to design and launch digital health Proof of Concepts in partnership with startups.
Today Gerry is the General Partner and Managing Director of the Digital Therapeutics division at Healthware Group, in charge of an evolving DTx pipeline. He holds a BFA degree from the State University of New York, and MBA credits at the University of Phoenix.

Gerry, how would you assess the current digital health landscape given the latest news?

Observing the news from the Digest, we can definitely find some important themes behind the latest happenings in digital health. […] These types of mental health support tools are critical, especially in the Covid and post-Covid times, because the incidence of mental health distress has become more and more prevalent across the world. […]
Almost a year ago as a part of a panel at Frontiers Health Global Conference we had a conversation with Alison Darcy, Founder and President at earlier mentioned Woebot Health (you can read the takeaways from this panel discussion in the Frontiers Health Booklet – editorial note). And we have seen that their company has grown a lot since then: $90M raised by Woebot Health in July 2021 is a very illustrative milestone. The same panel featured other notable digital menthal health companies such as Wysa, Silvercloud and Happify all of whom have had tremendous growth and investments in the last year.[…]

I would add that there are two other segments of mental health that have become more and more visible: solutions focusing on helping children and corporate solutions created for the benefit of employees under new work-related stress. What would be your insights around these two areas?

Children’s mental health is becoming a critical topic because their social interaction has become limited by lockdowns and remote learning. Social interactions with peers are, however, especially critical to the emotional development of children or adolescents. One of the concerns here is that the pandemic itself has created a strong dependance on digital tools and gadgets, which have resulted in an even bigger social bubble around young people. Hence, the question here is how do we integrate these tools in a proper way? […]

If you’re keen to learn more, you can read the full interview at www.healthwaregroup.com/blog

Omada Health announced the launch of Physician-Guided Care for diabetes and hypertension, creating the first virtual cardiometabolic clinic. Omada is adding virtual consultations with physicians for members who need more help controlling their conditions. Members will now have access to behavior change support, diabetes/hypertension management and education, devices and monitoring, and medical management of diabetes, hypertension, and dyslipidemia all in one place. The multidisciplinary, virtual clinic care team will include physicians, health coaches, and diabetes educators, working together to improve members’ health.

Coordinate date and care instructions

Individuals diagnosed with chronic conditions like diabetes and hypertension have to navigate a maze of silos to manage their conditions, including doctors, educational resources, monitoring devices, labs and medication. Coordinating data, care instructions and appointments across what can be dozens of touchpoints leads to gaps in care. Data shows between 30% and >90% of people with diabetes are not receiving elements of the care and support they need. Integrated clinics are working to tackle this challenge by combining care teams, appointments and data all in one place, but these in-person resources are scarce, costly and hard to scale.

Change people’s behaviour

Omada began building the foundation for an integrated virtual clinic ten years ago, by creating a digital platform driving lifestyle behavior change. Starting with that hardest challenge – changing people’s behavior – Omada has added care programs over the years for mental health, musculoskeletal conditions, and diabetes and hypertension management, as well as enhanced monitoring capabilities. This includes continuous glucose monitors that are now available to eligible members as a part of Omada’s diabetes program.

Now, with Physician-Guided Care, Omada is adding the ability to integrate medication prescription, medication management, and lab orders and results, providing the support a member needs between visits with their primary care physician in a truly scalable, accessible way.

Manage the bureaucracy of healthcare

For members, this level of care means their data and their care experiences are integrated and coordinated. Each care team member knows their health history, their latest CGM and other device readings, and has access to their lab data. The Member can access that same information, right on their smartphone. This data also flows back to the member’s primary care physician, when they have one. This all means the member doesn’t have to do the work of managing the bureaucracy of healthcare, and can instead focus on improving their health.

At Omada, we’re defining a new era of health ­­­– an era that is built on a belief that everyone with a chronic condition can improve their health, said Carolyn Jasik, MD, Omada Health’s Chief Medical Officer. Omada’s new, virtual-first care platform offers a way to supplement meaningful in-person care and create a surround sound experience for members battling complex conditions.

This expansion of Omada’s programs will help members have access to care that is more efficient, more effective, and integrated into the in-person ecosystem. The platform gives members tools to:

• Follow their care plans and meet their goals
• Make the most of in-person visits
• Securely access their own health information at any time
• Benefit from clinicians, coaches and specialists armed with their latest data
• Ultimately take control of their own health

Omada plans to expand its Physician-Guided Care into its pre-diabetes and weight management, behavioral health, and musculoskeletal programs starting in 2022.

To learn more, email PhysicianGuidedCare@omadahealth.com.

About Omada Health

Omada Health combines the latest clinical protocols with breakthrough behavior science to make it possible for people with chronic conditions to achieve long term improvements in their health. Working with over 1,500 customers – including Fortune 500 and small- and medium-sized employers, health plans, and health systems – the company delivers personalized interventions for diabetes and diabetes prevention, hypertension, musculoskeletal issues and behavioral health. Omada Health’s digital care programs are clinically supported and evidence-based, and have had its results published in multiple peer-reviewed journals. Omada builds programs that employees don’t just try, but stick with – resulting in reduced healthcare costs that deliver long term changes in health behavior and increased ROI.